Treatment resistant schizophrenia: Course of brain structure and function

Philip D Harvey, Jennifer B. Rosenthal

Research output: Contribution to journalArticle

9 Scopus citations


Approximately 30% of people with schizophrenia manifest a minimal response to conventional and atypical antipsychotic medications and manifest continuous symptoms of psychosis, with this condition referred to as "treatment resistant schizophrenia (TRS)". There are several neurobiological consequences of continuous psychosis, including regional cortical atrophy and ventricular enlargement. Pharmacological treatments are available for TRS, with at least 1/3 of patients responding to treatment with clozapine. In this paper we review the evidence regarding the course of treatment resistant schizophrenia, as well as changes in brain structure and function in psychosis and on the possible role of clozapine treatment in altering cortical deterioration in patients with TRS.

Original languageEnglish (US)
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
StateAccepted/In press - Oct 30 2015


  • Clozapine
  • Schizophrenia
  • Treatment resistance

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Fingerprint Dive into the research topics of 'Treatment resistant schizophrenia: Course of brain structure and function'. Together they form a unique fingerprint.

  • Cite this